Additionally, CARs targeting B cell maturation antigen (BCMA), a protein expressed on multiple myeloma cells, have demonstrated encouraging outcomes in clinical studies for the treatment of this hematologic malignancy. Here, TNFRSF17 is linked to plasma cell myeloma.